Market Research Report
Insulin Biosimilars - Global Market Outlook (2017-2023)
|Published by||Stratistics Market Research Consulting||Product code||599839|
|Published||Content info||167 Pages
Delivery time: 1-2 business days
|Insulin Biosimilars - Global Market Outlook (2017-2023)|
|Published: November 1, 2017||Content info: 167 Pages||
Stratistics MRC, are pleased to announce the latest publication of Global Insulin Biosimilars market. Growing pervasiveness of type 1 diabetes and ongoing approvals by the government authorities are nurturing the market growth. Some of the factors such as growing population exposures, technological developments and favorable medical repayment scenario in developed countries are poised to favour the market growth. However, patent protection rights of insulin and strong vengeance from the key manufacturers are some of the restraints limiting the market.
Expansion of clinically verified insulin biosimilar will cover the road for new entrants. The approaching patent expiration of insulin drugs will unlock new opportunities for the development of biosimilars and manufacturing companies. As cost is high due to strict observance requirements, prices of biosimilar drugs are anticipated to decrease as compared to branded drugs.
North America led the insulin biosimilars market due to rising demand for insulin in the region. Europe is anticipated to account for second largest share and Asia Pacific is expected to grow at a fastest rate during the forecast period. APAC players are competing on the basis of price and have pool of patients affected by diabetes, thus fueling the market growth.
Some of the key players in this market are Wockhardt Limited, Ypsomed AG, Pfizer Inc., Mylan N.V., Boehringer Ingelheim GmbH, NOVO Nordisk A/S, Sanofi S.A., Merck & Co., Biocon Limited and Eli Lilly & Co.
Biosimilars Types Covered:
Disease Indications Covered:
What our report offers:
List Of Tables